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Aneuploidy, an incorrect chromosome number, is
a hallmark of cancer. Compounds that cause lethality
in aneuploid, but not euploid, cells could therefore
provide new cancer therapies. We have identified
the energy stress-inducing agent AICAR, the protein
folding inhibitor 17-AAG, and the autophagy inhibitor
chloroquine as exhibiting this property. AICAR
induces p53-mediated apoptosis in primary mouse
embryonic fibroblasts (MEFs) trisomic for chromo-
some 1, 13, 16, or 19. AICAR and 17-AAG, especially
when combined, also show efficacy against aneu-
ploid human cancer cell lines. Our results suggest
that compounds that interfere with pathways that
are essential for the survival of aneuploid cells could
serve as a new treatment strategy against a broad
spectrum of human tumors.INTRODUCTION
Aneuploidy, a condition in which the chromosome number is not
a multiple of the haploid complement, is associated with death
and disease in all organisms in which this has been studied. In
budding and fission yeast, aneuploidy inhibits proliferation
(Niwa et al., 2006; Torres et al., 2007). In flies and worms, most
or all whole-chromosome trisomies and monosomies are lethal,
respectively (Hodgkin, 2005; Lindsley et al., 1972). In the mouse,
all monosomies and all trisomies but trisomy 19 result in embry-
onic lethality. In humans, all whole-chromosome aneuploidies
except trisomy 13, 18, or 21 lead to death during embryogenesis.
The viable trisomies display severe abnormalities (Lin et al.,
2006; Moerman et al., 1988; Antonarakis et al., 2004).
Aneuploidy is also detrimental at the cellular level. Budding
and fission yeast cells carrying an additional chromosome
display cell proliferation defects (Niwa et al., 2006; Pavelka
et al., 2010; Torres et al., 2007). Primary aneuploid mouse
embryonic fibroblasts (MEFs) trisomic for any of four chromo-
somes, chromosome 1, 13, 16, or 19, primary foreskin fibroblast
cells derived from Down’s syndrome individuals (trisomy 21),
and human cell lines with decreased chromosome segregation
fidelity exhibit cell proliferation defects (Segal and McCoy,
1974; Thompson and Compton, 2008; Williams et al., 2008).Two systematic studies in disomic budding yeasts and trisomic
MEFs furthermore showed that the presence of an additional
chromosome elicits a set of phenotypes that is shared between
different aneuploidies in both yeast and mouse. Yeast cells
carrying an additional chromosome display metabolic alter-
ations and increased sensitivity to compounds that interfere
with protein folding and turnover (Torres et al., 2007). These
shared traits are due to the additional proteins produced from
the additional chromosomes (Torres et al., 2007). Similar pheno-
types are seen in trisomic MEFs. Trisomic cells show increased
sensitivity to proteotoxic compounds, higher basal levels of au-
tophagy, elevated amounts of the active form of the molecular
chaperone Hsp72 (see below), and increased uptake of gluta-
mine, a major carbon source for the TCA cycle (DeBerardinis
et al., 2007; Williams et al., 2008). Based on these findings, it
was proposed that aneuploidy leads to a cellular response
(Torres et al., 2010; Torres et al., 2007). Cells engage protein
degradation and folding pathways in an attempt to correct
protein stoichiometry imbalances caused by aneuploidy. This
increases the load on the cell’s protein quality control pathways
and results in heightened sensitivity to proteotoxic compounds
and an increased need for energy. Whether the cell proliferation
defects that are observed in aneuploid cells are also a part of the
response to the aneuploid state, as is seen in many other stress
responses, or are caused by the misregulation of individual cell
cycle proteins is not yet known.
Although aneuploidy adversely affects cell proliferation, the
condition is associated with a disease characterized by
unabated growth, cancer (reviewed in Luo et al. [2009]). More
than 90% of all solid human tumors carry numerical karyotype
abnormalities (Albertson et al., 2003). Studies in mouse models
of chromosome instability indicate that aneuploidy is not simply
a by-product of the disease but is directly responsible for tumor
formation. Impairing spindle assembly checkpoint activity or
halving the gene dosage of the motor protein CENP-E causes
chromosome missegregation. Remarkably, it also causes
increased tumor formation in mice (Li et al., 2010; Sotillo et al.,
2007; Weaver et al., 2007). How aneuploidy promotes tumori-
genesis despite its antiproliferative effects is an important ques-
tion that remains to be answered.
Irrespective of how aneuploidy promotes tumorigenesis, the
stresses caused by the aneuploid state could still exist in aneu-
ploid cancer cells, a condition termed ‘‘nononcogene addiction’’
(Luo et al., 2009). Compounds that exhibit lethality with the
aneuploid state either by exaggerating the adverse effects ofCell 144, 499–512, February 18, 2011 ª2011 Elsevier Inc. 499
aneuploidy and/or by interfering with pathways that are essential
for the survival of aneuploid cells could represent new tumor
treatments. We have identified the energy and proteotoxic
stress-inducing compounds AICAR, 17-AAG, and chloroquine
as exhibiting this selectivity. They induce p53-mediated
apoptosis in primary mouse embryonic fibroblasts trisomic for
chromosome 1, 13, 16, or 19. AICAR and 17-AAG also show
efficacy against aneuploid human cancer cell lines. When
combined, the two compounds are more effective in inhibiting
the proliferation of human colorectal cancer cells that exhibit
high-grade aneuploidy (chromosome instability lines, CIN)
compared to lines that show low-grade aneuploidy (microsatel-
lite instability lines, MIN). Our results raise the interesting possi-
bility that the aneuploid state of a cancer cell can be exploited in
cancer therapy.
RESULTS
Identification of Compounds that Preferentially
Antagonize the Proliferation of Aneuploid Cells
To identify compounds that exhibit adverse synthetic interac-
tions with the aneuploid state, we employed MEFs trisomic for
chromosome 1, 13, 16, or 19. We generated these cells using
mice that carry Robertsonian fusion chromosomes (Williams
et al., 2008) and compared their drug response to that of litter-
mate control cells that carry a Robertsonian chromosome but
are euploid (note that these controls were included in all experi-
ments described here). Chromosomes 1, 13, 16, and 19 were
chosen because they cover a large portion of the size and coding
spectrum of mouse chromosomes (Chr1, 197 Mbp and 1228
genes; Chr13, 120 Mbp and 843 genes; Chr16, 98 Mbp and
678 genes; and Chr19, 61 Mbp and 734 genes) (Williams et al.,
2008).
Because aneuploidy leads to cell proliferation defects as well
as proteotoxic and energy stress (Torres et al., 2007; Williams
et al., 2008; reviewed in Luo et al., 2009), we selected
compounds with similar effects, with the rationale that further
interference with pathways that are already impaired in aneu-
ploids or are essential for their viability may lead to lethality.
We tested compounds that cause genotoxic stress (aphidocolin,
camptothecin, cisplatin, doxorubicin, and hydroxyurea; see
Supplemental Information available online for effects of these
compounds), proteotoxic stress (17-allylamino-17-demethoxy-
geldanamycin [17-AAG], cycloheximide, chloroquine, lactacys-
tin, MG132, puromycin, and tunicamycin), and energy stress
(5-aminoimidazole-4-carboxamide riboside [AICAR], compound
C, 2-deoxyglucose, metformin, rapamycin, and torin1). Approx-
imately 2 3 105 MEFs were plated into 6-well plates and, after
24 hr, were exposed to compound or vehicle alone. The effects
on cell number were determined for 3 days. Because cell accu-
mulation is impaired in trisomic cells even in the absence of treat-
ment (Williams et al., 2008) (Figure 1A), cell number is presented
as a percentage of cells observed in the absence of treatment.
For a few compounds (e.g., aphidicolin), this percentage is
greater in some trisomic cells than in euploid controls (Table S1).
Though this indicates that trisomic cells tolerate the compound
better than euploid cells, it is important to note that trisomic cells
still grow significantly worse than euploid cells.500 Cell 144, 499–512, February 18, 2011 ª2011 Elsevier Inc.The majority of compounds did not exhibit selectivity toward
trisomic MEFs or did so for only a subset of the trisomies tested
(Table S1). However three compounds—the energy stress
inducer AICAR, the Hsp90 inhibitor 17-AAG, and the autophagy
inhibitor chloroquine—impaired the accumulation of all four
trisomic MEFs to a higher degree than that of euploid control
cells (Table S1).
AICAR is a cell-permeable precursor of ZMP (an AMP analog),
which allosterically activates AMP-activated protein kinase
(AMPK), thereby mimicking energy stress (Corton et al., 1995).
AMPK is sensitive to the intracellular AMP:ATP ratio and upregu-
lates catabolic pathways to produce more ATP and downregu-
lates anabolic pathways to conserve energy charge (Hardie,
2007). AICAR significantly inhibited the accumulation of cells
trisomic for the large chromosomes 1 and 13. Accumulation of
cells carrying the gene-poorer chromosome 16was less affected
(Figure 1). Proliferation of cells trisomic for the smallest chromo-
some, chromosome 19, was only subtly inhibited by AICAR (Fig-
ure 1). Importantly, whereas euploid cells continued to proliferate
in the presence of high concentration of AICAR (0.5 mM), cell
numbers declined in all trisomic cultures (Figure 1A), indicating
that AICAR in fact kills trisomic MEFs. Treatment of cells with
metformin, a type 2 diabetes drug that also induces energy
stress and activates AMPK (Canto´ et al., 2009), also impaired
the accumulation of trisomy 13 and 16 cells in culture, although
the effects were not as dramatic (Table S1 and Figure S1A).
However, 2-deoxyglucose, which also causes AMPK activation
(Figures S1B and S1C), did not show selectivity for trisomic cells
(Figure S1D). In fact, 2-deoxyglucose was highly toxic even in
euploid cells (Figure S1D). Why AICAR, metformin, and 2-deox-
yglucose show different efficacy in trisomic MEFs, despite both
causing AMPK activation, is at present unclear (see Discussion).
17-AAG inhibits the chaperone Hsp90. This chaperone
together with others is needed for the folding, activation, and
assembly of a specific set of client proteins (Young et al.,
2001). 17-AAG inhibited proliferation of all aneuploid cells at
a concentration of 100 nM (Figure 2A and Table S1). Further-
more, cells trisomic for the largest chromosome, Chr1, exhibited
higher sensitivity to the compound than cells harboring an
additional copy of the smaller chromosomes, Chr16 or 19. This
finding suggests that aneuploid cells rely on protein quality
control pathways for their survival, which is consistent with the
finding that levels of the chaperone Hsp72 are increased in
trisomic MEFs (Figure 5D).
Chloroquine also induces proteotoxic stress because it
inhibits late stages of autophagy, a homeostatic mechanism
that is critical for the elimination of damaged proteins and
organelles (Levine and Kroemer, 2008; Mizushima et al., 2008).
Chloroquine preferentially inhibited the proliferation of trisomic
MEFs, although the antiproliferative effects were not as dramatic
as those caused by AICAR or 17-AAG. Similar results were ob-
tained when autophagy was impaired by the knockdown of the
autophagy factor Beclin 1 in trisomy 13 cells (Figure S1E). As
observed for AICAR and 17-AAG, the increased sensitivity of
trisomic cells correlated with the size of the additional chromo-
some (Figure 2B and Table S1). We conclude that interference
with autophagy is detrimental in aneuploid MEFs, perhaps
because aneuploid cells rely on autophagy to produce energy
AC
el
l n
um
be
r (
x1
05
)
0 24 48 72
0
1
2
3
4
5
6
7
Time (h)
Ts1
Ts1+0.2mM
Ts1+0.5mM
WT
WT+0.2mM
WT+0.5mM
R
el
at
iv
e 
ce
ll 
nu
m
be
r
0 0.2 0.5
   0
0.2
0.4
0.6
0.8
1.0
1.2
AICAR (mM)
WT
Ts1
0 24 48 72
0
1
2
3
4
5
6
7
Time (h)
C
el
l n
um
be
r (
x1
05
)
Ts13
Ts13+0.2mM
Ts13+0.5mM
WT
WT+0.2mM
WT+0.5mM
0 0.2 0.5
   0
0.2
0.4
0.6
0.8
1.0
1.2 WT
Ts13
AICAR (mM)
R
el
at
iv
e 
ce
ll 
nu
m
be
r
0 24 48 72
0
1
2
3
4
5
6
7
Time (h)
C
el
l n
um
be
r (
x1
05
)
Ts16
Ts16+0.2mM
Ts16+0.5mM
WT
WT+0.2mM
WT+0.5mM
   0
0.2
0.4
0.6
0.8
1.0
1.2
AICAR (mM)
0 0.2 0.5
WT
Ts16
R
el
at
iv
e 
ce
ll 
nu
m
be
r
0 24 48 72
0
1
2
3
4
5
6
7
Time (h)
C
el
l n
um
be
r (
x1
05
)
Ts19
Ts19+0.2mM
Ts19+0.5mM
WT
WT+0.2mM
WT+0.5mM
0 0.2 0.5
   0
0.2
0.4
0.6
0.8
1.0
1.2
AICAR (mM)
WT
Ts19
R
el
at
iv
e 
ce
ll 
nu
m
be
r
B
**
**
**
**
**
**
*
*
Figure 1. AICAR Inhibits Proliferation in
Trisomic MEFs
(A) Wild-type (filled symbols) and trisomic primary
(open symbols) MEFs were grown for 72 hr either
in the absence (circles) or presence (0.2 mM,
triangles; 0.5 mM, squares) of AICAR, and cell
number was determined at the indicated times.
(B) Cell number of wild-type (filled bars) and
trisomic cells (open bars) was determined after
3 days and is shown as the percentage of the
untreated control. The data are the mean of three
independent experiments ± standard deviation.
*p < 0.05; **p < 0.005; t test.
See also Table S1 and Figures S1A–S1D.and/or reduce proteotoxic stress. Indeed, autophagy is
increased in trisomic MEFs (Figures 5A–5C).
Interestingly, the combined treatment of trisomic cells with
AICAR and 17-AAG significantly impaired the proliferative abili-
ties of trisomic MEFs but had little effect on euploid control
cultures (Figure 2C). Similar results were obtained when cells
were treated with a combination of AICAR and chloroquine (Fig-
ure 2D). We conclude that compounds exist that selectively
inhibit the proliferation of trisomic MEFs. Their combinedCell 144, 499–512,application, especially, leads to signifi-
cant differential effects in euploid and
aneuploid cells.
AICAR, 17-AAG, and Chloroquine
Induce Apoptosis in Trisomic MEFs
To examine how AICAR, 17-AAG, and
chloroquine preferentially antagonize
the proliferation of trisomic MEFs, we
asked whether the compounds induce
apoptosis in trisomic, but not euploid,
cells. At high dose, AICAR inhibits the
proliferation of wild-type MEFs by
inducing cell-cycle arrest and apoptosis
(Jones et al., 2005) (Figure 3). At a concen-
tration of 0.2 mM, AICAR did not induce
apoptosis in wild-type cells, but 0.5 mM
AICAR led to a 66% increase in early
apoptotic cells (Figures 3A and 3B). The
effects of AICAR on trisomic cells were
more dramatic. Apoptosis was not
increased in untreated trisomic MEFs,
but addition of 0.2 or 0.5 mM AICAR led
to a 2-fold increase in early apoptotic
cells (Figures 3A and 3B). 17-AAG and
chloroquine also induced apoptosis in
trisomy 13 MEFs (Figure 3C).
Is apoptosis the only antiproliferative
effect of the identified compounds? We
addressed this question for AICAR. We
did not detect substantial cell cycle
delays in AICAR-treated trisomic MEFs
(Figure S2A), although subtle cell cycle
alterations cannot be excluded whenexamining unsynchronized cells. AICAR did not appear to induce
premature senescence in trisomic MEFs either, as judged by the
production of senescence-associated b-galactosidase (Fig-
ure S2B). Treatment of cells with necrostatin-1 (Nec-1), an inhib-
itor for necroptosis (Degterev et al., 2005), did not suppress the
antiproliferative effects of AICAR either (Figure S2C). AICAR is
known to inhibit the mTOR pathway (Sarbassov et al., 2005).
Inhibition of the mTOR pathway either through treatment of
cells with the mTOR kinase inhibitors rapamycin or torin1 orFebruary 18, 2011 ª2011 Elsevier Inc. 501
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Figure 2. The Proteotoxic Compounds 17-AAG and Chloroquine Exaggerate the Antiproliferative Effects of AICAR
(A and B)Wild-type (filled bars) and trisomic cells (open bars) were treatedwith the indicated concentrations of 17-AAG (A) or chloroquine (B), and cell number was
determined after 3 days.
(C and D) Cells were treated with 0.2 mMAICAR and the indicated concentrations of 17-AAG (C) or chloroquine (D). Cell number was determined after 3 days. The
data are the mean of three independent experiments ± standard deviation. *p < 0.05; **p < 0.005; t test.
See also Table S1 and Figure S1E.through knockdown of mTOR neither inhibited the proliferation
of trisomic MEFs nor enhanced the antiproliferative effects of
AICAR (Figure S3). We conclude that AICAR treatment inhibits
proliferation by increasing apoptosis in trisomic MEFs. 17-AAG
and chloroquine have a similar effect, at least, in trisomy 13 cells.502 Cell 144, 499–512, February 18, 2011 ª2011 Elsevier Inc.The Antiproliferative Effects of AICAR Are Mediated
by AMPK and p53
How do AICAR, 17-AAG, and chloroquine induce apoptosis in
trisomic MEFs? We addressed this question for AICAR. First,
we testedwhetherAICARantagonizes theproliferationof trisomic
MEFs by affecting AMPK. Knockdown of AMPK using short hair-
pins not only effectively lowered AMPK protein levels (Figure 4A),
but also ameliorated the cell accumulation defect brought about
by AICAR treatment (Figure 4B; note that the effects of AICAR
treatment were assessed after only 24 hr in this experiment).
Thus, its effects on control trisomic cells were not as dramatic
as after 3 days, as is shown in Figure 1B). Inhibition of AMPK by
othermeanshadsimilar effects.CompoundC isapyrazolopyrimi-
dine compound that functions as an ATP-competitive inhibitor of
AMPK and other protein kinases (Bain et al., 2007). Treatment
with compound C increased the proliferative abilities of trisomic
cells (Figure 4C) and suppressed the adverse effects of AICAR
(Figure 4D). AICAR thus inhibits the accumulation of trisomic
MEFs, at least in part, by activating AMPK.
The sensitivity of trisomic cells to AICAR could be due to hy-
peractivation of AMPK in trisomic, but not euploid, cells. To
test this possibility, we measured AMPK activity in euploid and
aneuploid MEFs in the presence or absence of AICAR. The basal
activity of AMPK was not increased in untreated trisomic MEFs,
as judged by in vitro AMPK kinase assays and phosphorylation
of Threonine 172 on AMPK, a modification that is indicative of
active AMPK (Lamia et al., 2009) (Figures 4E and 4F). AMPK acti-
vation occurred faster in aneuploid MEFs upon AICAR treatment
(Figure 4G), but the degree of activation was similar in euploid
and aneuploid MEFs 24 hr after AICAR addition (Figures 4E
and 4F). We conclude that hyperactivation of AMPK is not
responsible for the adverse effects of AICAR on trisomic MEFs.
However, our results suggest that AMPK is activated more
readily by AICAR in trisomic cells.
Having established that the effects of AICAR on trisomic cells
are, at least in part, mediated by AMPK activation, we next deter-
mined how this could lead to apoptosis. AMPK activates p53
through phosphorylation of Serine15 (Jones et al., 2005). We
find that AICAR treatment subtly induced S15 phosphorylation
and p53 stabilization in both wild-type and trisomy 13MEFs (Fig-
ure 3D), but both events occurred significantly faster in trisomy13
cells (Figure 3D). We also examined two p53 targets, the CDK
inhibitor p21 and the proapoptotic protein Bax. p21 protein levels
were not increased in response to AICAR treatment. In contrast,
Bax activitywas (Figures 3Dand3E). Bax integrates into theouter
membrane of mitochondria, causing the activation of the
apoptotic program (VanderHeiden andThompson, 1999). AICAR
treatment led to an increase in mitochondrially associated Bax in
both wild-type and trisomy 13 cells, but the amount of Bax asso-
ciated with this organelle fraction was higher in trisomy 13 cells
(Figure 3E). These results suggest that p53 induces apoptosis
in trisomic MEFs. Consistent with this idea, we find that p53
knockdown suppressed the antiproliferative effects of AICAR in
trisomy 13 and 16 MEFs (Figures 3F and 3G). We conclude that
the antiproliferative effects of AICAR in trisomic cells are, at least
in part, mediated by p53-mediated apoptosis. 17-AAG and chlo-
roquine-induced apoptosis also depend on this transcription
factor, at least in trisomy 13 cells (Figure S4).
AICAR Exaggerates the Cellular Stresses Caused
by Aneuploidy
AICAR treatment leads to increased p53-dependent apoptosis
in trisomic, but not euploid, MEFs. However, other compoundsthat induce p53-mediated apoptosis, i.e., genotoxic com-
pounds, do not show this selectivity. This indicates that, in addi-
tion to inducing p53, AICAR must have other adverse effects on
trisomic MEFs. The increased sensitivity of aneuploid cells to
AICAR could be due to aneuploidy and AICAR affecting parallel
pathways and/or due to AICAR exaggerating defects that are
already present in trisomic MEFs. To test the latter possibility,
we analyzed proteotoxic stress indicators in trisomic cells in
the presence and absence of AICAR.
In both aneuploid budding yeasts and MEFs, the majority of
genes located on an additional chromosome are expressed
(Pavelka et al., 2010; Torres et al., 2007, 2010; Williams et al.,
2008). This observation, together with the finding that aneuploid
yeast cells are sensitive to conditions that interfere with protein
folding and turnover, led to the proposal that, in yeast, excess
proteins that are produced by the additional chromosomes place
stress on the cell’s protein quality control systems (Torres et al.,
2007, 2010). To determine whether trisomicMEFs are under pro-
teotoxic stress, we examined basal levels of autophagy and the
Hsp72 chaperone in trisomic MEFs and their behavior in
response to AICAR treatment. During autophagy, the autopha-
gosomal membrane component LC3 is lipidated and incorpo-
rated into autophagosomal structures (Mizushima et al., 2008).
In the absence of AICAR, trisomy 13 and 16 cells contained
increased levels of LC3 mRNA and lipidated LC3 that was incor-
porated into autophagosomes (Figures 5A and 5C). Expression
of Bnip3, a component of the autophagy machinery that is
induced by many different stresses (Mizushima and Klionsky,
2007), was also increased in trisomy 13 and 16MEFs (Figure 5B).
AICAR treatment further induced Bnip3 expression as well as
LC3 expression and LC3 incorporation into autophagosomes
(Figures 5A–5C).
Trisomic MEFs also harbor elevated levels of the inducible
form of the chaperone Hsp72 (Figure 5D). AICAR treatment led
to a further increase in Hsp72 levels in all but trisomy 16 cells
in which Hsp72 levels were already very high (Figure 5D). Our
results indicate that the activities of protein quality control path-
ways are elevated in aneuploid MEFs. They further show that
AICAR enhances the proteotoxic stress present in aneuploid
cells. We propose that this enhancement of the proteotoxic
stress in trisomic cells contributes to the aneuploidy-selective
antiproliferative effects of AICAR.
AICAR and 17-AAG Inhibit the Proliferation
of Primary MEFs with Decreased Chromosome
Segregation Fidelity
Having characterized the effects of AICAR, 17-AAG, and chloro-
quine on defined aneuploidies, the trisomic MEFs, we next
wanted to determine whether the compounds also inhibit prolif-
eration of MEFs in which aneuploidies are spontaneously gener-
ated due to increased chromosomemissegregation. To this end,
we tested the effects of AICAR and 17-AAG on primary MEFs
with a compromised spindle assembly checkpoint (SAC). Partial
inactivation of the SAC by impairing BUBR1 function using the
hypomorphic Bub1bH/H allele or by expressing a checkpoint-
resistant CDC20 allele (Cdc20AAA) causes chromosome misse-
gregation and the accumulation of aneuploid cells in culture
over time (Baker et al., 2004; Li et al., 2009). Primary MEFsCell 144, 499–512, February 18, 2011 ª2011 Elsevier Inc. 503
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Figure 3. AICAR, 17-AAG, and Chloroquine Induce Apoptosis in Trisomic MEFs
(A) Wild-type (top) and trisomy 1 cells (bottom) were treated with AICAR for 24 hr, and apoptosis wasmeasured using annexin V-FITC/ PI staining. Early apoptotic
cells are found in the bottom-right quadrant.
(B and C) Quantification of the percentage of annexin V-FITC-positive, PI-negative cells in wild-type, trisomy 1, and trisomy 13 cultures 24 hr after AICAR
treatment (B) and in wild-type and trisomy 13 cultures 24 hr after 17-AAG or chloroquine treatment (C).
(D) Wild-type and trisomy 13 cells were treated with 0.2 mM AICAR and p53 Serine 15 phosphorylation and p53 and p21 protein levels were analyzed.
Quantifications of the ratio of phosphorylated p53/actin protein are shown under the P-p53 blot. The ratios were normalized to untreated wild-type cells. Asterisk
denotes S15 phosphorylated p53.
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carrying these mutations were sensitive to 17-AAG and AICAR
(Figures 6A and 6B). The effects were not as dramatic as in the
trisomic MEFs, presumably because only 36% and 52% of the
Bub1bH/H and Cdc20AAA MEFs are aneuploid after several
passages, respectively (Baker et al., 2004; Li et al., 2009). Our
results indicate that AICAR and 17-AAG also antagonize the
proliferation of MEFs with decreased chromosome segregation
fidelity.
AICAR and 17-AAG Inhibit Proliferation of Aneuploid
Human Cancer Cells
A key question that arises from our findings is whether AICAR,
17-AAG, and chloroquine also show efficacy against aneuploid
cancer cell lines. To address this question, we analyzed the
effects of these compounds on the proliferative abilities of colo-
rectal cancer cell lines with high-grade aneuploid karyotypes
(CIN lines) and of colorectal cell lines with near-euploid karyo-
types (MIN lines) (Cunningham et al., 2010). MIN (microsatellite
instability) colorectal cancer lines (HCT-116, HCT-15, DLD-1,
SW48, and LoVo) maintain a near-euploid karyotype (Bhatta-
charyya et al., 1994) (Figure 6C); CIN (chromosome instability)
colorectal cell lines (Caco2, HT-29, SW403, SW480, and
SW620) harbor between 50 and 100 chromosomes (Rajagopalan
et al., 2003) (Figure 6C). Chloroquine did not affect CIN or MIN
tumor cell line growth (Figure S5A), which is perhaps not
surprising given the compound’s modest antiproliferative effects
in trisomic MEFs. AICAR and 17-AAG showed greater growth
inhibitory effects in CIN cell lines than in MIN cell lines or in
euploid cell lines (CCD112 CoN and CCD841 CoN) (Figure 6C).
Treating cells with both AICAR and 17-AAG had an even more
significant differential effect (Figure 6C).
We also examined the effects of AICAR, 17-AAG, and chloro-
quine on aneuploid lung cancer cell lines. As in colorectal cancer
cell lines, chloroquine did not show a differential effect in lung
cancer cell lines (Figure S5B). The effects of AICAR on lung
cancer cell linesweremodest. Of the eight aneuploid lung cancer
lines examined (A549, NCI-H520, NCI-H838, NCI-H1563,
NCI-H1792, NCI-H2122, NCI-H2170, and NCI-H2347), only
a subset of cell lines exhibited sensitivity to AICAR (Figure 6D).
However, all eight cell lines showed significant sensitivity toward
17-AAG. Furthermore, a slight additive effect between AICAR
and 17-AAG at high concentrations of compound (0.2 mM
AICAR + 200 nM 17-AAG) was observed (Figure 6D; p = 0.03).
Interestingly, all aneuploid cancer cell lines exhibited increased
sensitivity to AICAR and/or 17-AAG, irrespective of whether
p53 was functional or not (Figures 6C and 6D; see Discussion).
AICAR and 17-AAG also inhibited tumor cell growth in
xenograft models. Two MIN (HCT15 and LoVo) and two CIN
(HT29 and SW620) cell lines were injected into the flanks of
immunocompromised mice and were then treated with AICAR,(E) Wild-type and trisomy 13 cells were treated with 0.2 or 0.5 mM AICAR for 24 h
for the presence of Bax by immunoblotting. Mitochondrial Hsp60 served as loadin
Bax/total Bax protein normalized to untreated wild-type cells are shown under th
(F) p53 knockdown efficiency revealed by immunoblotting using an anti-p53 anti
(G) Cells were transfected with a p53 knockdown shRNA and treated with AICAR
experiments ± standard deviation. *p < 0.05; **p < 0.005; t test.
See also Figure S2, Figure S3, and Figure S4.17-AAG, or both compounds. Consistent with the cell culture
analyses, the combination treatment wasmore effective in inhib-
iting CIN tumor growth than in preventing MIN tumor growth
(Figures 7A and 7B). The reduced ability of CIN lines to form
tumors could, in part, be due to increased apoptosis. The two
CIN lines, but not the MIN lines, exhibited high levels of
apoptosis when treated with AICAR or AICAR+17-AAG in culture
(Figure 7C). Furthermore, as in trisomic MEFs, AICAR treatment
induced the transcription of a number of autophagy genes in the
two CIN (HT29 and SW620) cell lines, but not the two MIN
(HCT15 and LoVo) cell lines, and increased the levels of the lipi-
dated form of LC3 (Figure S6). Hsp72 levels were also higher in
CIN lines, but AICAR did not cause a further increase in Hsp72
levels (Figure S6B). AICAR and 17-AAG most likely inhibit tumor
cell growth in multiple ways. Our results raise the interesting
possibility that one reason for their growth inhibitory effect is
the aneuploid state of these cancer cells.
DISCUSSION
A Response to the Aneuploid State
In yeast, aneuploidy causes cell proliferation defects and
increased sensitivity to proteotoxic stress (Torres et al., 2007).
The data presented here together with our previous analyses
of trisomic MEFs (Williams et al., 2008) indicate that the conse-
quences of aneuploidy in mouse cells are remarkably similar to
those in yeast. Cell proliferation is impaired (Williams et al.,
2008), and cells show signs of energy and proteotoxic stress
(Williams et al., 2008 and this study). Cells take up more gluta-
mine and are sensitive to the energy stress-causing compound
AICAR. Autophagy and active Hsp72 are elevated in trisomic
MEFs, and cells are sensitive to compounds that induce proteo-
toxic stress. It thus appears that the effects of aneuploidy on
cell physiology are conserved across species. The findings
described here also lend further support to our previous
proposal (Torres et al., 2007; Williams et al., 2008) that cells
respond to the aneuploid state by engaging protein quality
control pathways in an attempt to correct protein stoichiometry
imbalances caused by aneuploidy. Two recent studies showed
that p53 is also part of this response (Li et al., 2010; Thompson
and Compton, 2010). We did not detect elevated levels of active
p53 in trisomic MEFs. We speculate that aneuploidy of a single
chromosome is not sufficient to induce a p53 response.
Single-Chromosome Gains as a Model for Aneuploidy
in Cancer
We have used single chromosome gains to study the effects of
aneuploidy on cell physiology. But can this type of aneuploidy
also shed light on the role of aneuploidy in tumorigenesis? Single
chromosomal gains rarely occur in cancer. Instead, severer. Equal amounts of cytoplasmic or mitochondrial protein extracts were probed
g control in mitochondrial extracts. Quantifications of the ratio of mitochondrial
e mitochondrial Bax blot.
body. Actin serves as a loading control in western blots.
for 24 hr at the indicated doses. The data are the mean of three independent
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Figure 4. AICAR Antagonizes Proliferation of Trisomic MEFs in an AMPK-Dependent Manner
(A) AMPKa knockdown efficiency revealed by immunoblotting using an anti-AMPK antibody.
(B) Cells infected with either empty vector or an AMPKa knockdown construct were counted 24 hr after AICAR treatment.
(C) Wild-type (filled bars) and trisomic (open bars) cells were treated with the indicated concentrations of compound C for 3 days. Even though the effects of
compound C were less severe in trisomic cells than in euploid controls, it is important to note that the treated trisomic cells grew poorly compared to euploid
control cells.
(D) Wild-type (filled bars) and trisomic cells (open bars) were treated with 0.5 mM AICAR and compound C at the indicated doses for 3 days, and cell number was
counted.
(E and F) AMPK activity was analyzed by determining the extent of threonine172 phosphorylation on AMPK (E) or by in vitro kinase assays using the substrate
peptide IRS-1 S789 (F) in wild-type and trisomic cells after 24 hr of AICAR treatment. Quantifications of the ratio of phosphorylated AMPK/total AMPK protein
normalized to untreated wild-type cells are shown under the P-AMPK blot.
(G) AMPK activity was measured by in vitro kinase assays at the indicated time point following addition of 0.2 mM AICAR. The data are the mean of three
independent experiments ± standard deviation. *p < 0.05; **p < 0.005; t test.karyotypic abnormalities involving many chromosomes and
often multiple copies of individual chromosomes are the norm.
Despite this difference in degree of aneuploidy, we believe that506 Cell 144, 499–512, February 18, 2011 ª2011 Elsevier Inc.single chromosome gains can speak to the role of aneuploidy
in cancer for the following reasons. First, important features
and traits of the aneuploid state can be deduced from the
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Figure 5. AICAR Exaggerates the Stressed State of Trisomic MEFs
(A) Lipidated LC3-II was analyzed by immunoblotting in wild-type and trisomy 13 and 16 cells after 24 hr of AICAR treatment. Quantifications of the ratio of
lipidated LC3II /actin protein normalized to untreated wild-type cells are shown under the LC3-II blot.
(B) Quantitative RT-PCR analysis of mRNA abundance of the autophagy genes ATG1,ATG4,Beclin1, LC3,BNIP3, andGAPRAPL1. mRNA levels were quantified
in untreatedwild-type (black bars) and trisomic (white bars) cells as well as wild-type (gray bars) and trisomic (blue bars) cells treated with 0.5 mMAICAR for 24 hr.
RNA levels were normalized to those of the ribosomal RPL19 gene.
(C) The extent of autophagy was quantified by determining the number of LC3-GFP puncta in cells. Typical images are shown as examples for LC3-GFP puncta
formation in trisomy 13 and 16 and wild-type cells after AICAR treatment (left). Incubation in HBSS induces acute starvation and served as a positive control.
At 24 hr after AICAR treatment, the number of cells that harbor more than 4 LC3-GFP puncta was determined (right). The data are the mean of three independent
experiments ± standard deviation. *p < 0.05; **p < 0.005; t test.
(D) Wild-type and trisomic MEFs were treated with AICAR at the indicated doses, and levels of inducible Hsp72 were determined by immunoblotting.
Quantifications of the ratio of inducible Hsp72/Hsp90 protein normalized to untreated wild-type cells are shown underneath the Hsp72 blot.analysis of multiple single chromosomal abnormalities because
phenotypes shared by cells carrying different single additional
chromosomes will also exist in cells with multiple chromosomal
abnormalities. In fact, the protein stoichiometry imbalances
caused by aneuploidy and the proteotoxic and energy stresses
that these imbalances elicit will, if anything, bemore pronounced
in cells with multiple numeric chromosomal abnormalities.
Second, in some cancers, premalignant lesions or low-grade
tumors show limited chromosomal gains or losses. For example,small adenomas and atypical ductal hyperplastic lesions show
a low degree of loss of heterozygosity (Larson et al., 2006;
Shih et al., 2001). The study of single chromosomal abnormalities
could therefore provide important insights into the early stages of
tumorigenesis. Finally, the compounds that we discovered to
inhibit the proliferation of trisomic MEFs also showed efficacy
against aneuploid human cancer cell lines, suggesting that the
trisomy system can be employed to reveal features of aneuploid
tumor cells.Cell 144, 499–512, February 18, 2011 ª2011 Elsevier Inc. 507
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Figure 6. AICAR and 17-AAG Inhibit the Proliferation of MEFs with Decreased Chromosome Segregation Fidelity and of Aneuploid Human
Cancer Cells
(A and B) Wild-type (filled bars) and Bub1bH/H cells (open bars, A) or wild-type (filled bars) and Cdc20AAA cells (open bars, B) were treated with the indicated
concentrations of AICAR, 17-AAG, or both, and cell number was determined after 3 days. The data are the mean of three independent experiments ± standard
deviation. *p < 0.05; **p < 0.005; t test.
(C) Cells were treated with the indicated concentration of AICAR (top) or 17-AAG (center) or both compounds (bottom). Cell number was determined 3 days after
the addition of compound and is shown as the percentage of the untreated control. Primary euploid cells (black symbol), MIN colon cancer cell lines (blue, green
symbols) and aneuploid CIN colon cancer cells (red, purple symbols) were analyzed.
(D) Cell number of euploid (black symbols) and aneuploid lung cancer cells (red, purple symbols) was determined after 3 days of treatment with the indicated
compounds and is shown as the percentage of the untreated control. The data presented are the mean and the p value results of t test. NS, not significant.
See also Figure S5.Compounds that Synergize with the Aneuploid State
Among 18 compounds, we identified three, AICAR, 17-AAG, and
chloroquine, that exhibit synthetic interactions with four different508 Cell 144, 499–512, February 18, 2011 ª2011 Elsevier Inc.trisomic MEF lines. This specificity indicates that the interactions
observed are not simply a consequence of inflicting further harm
on already severely impaired cells but that the compounds
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Figure 7. AICAR and 17-AAG Inhibit Growth of Human Colon Cancer
Cells in Xenografts
(A) Mice were implanted with 4 3 106 MIN cells on the left flank and with the
same number of CIN cells on the right flank. Seven days after injection
(indicated by the arrow), mice were treated with daily i.p. injections of AICAR,
17-AAG, both, or PBS. Tumor volume (mm3) was measured at the indicated
time points and shown as mean tumor volumes.
(B) Mice treated with PBS (left) or AICAR+17AAG (right) 25 days after trans-
plantation.
(C) Quantification of the percentage of annexin V-FITC-positive, PI-negative
cells in wild-type, MIN, and CIN cell cultures 24 hr after AICAR or AICAR+17-
AAG treatment. The data are the mean of three independent experiments ±
standard deviation. *p < 0.05; **p < 0.005; t test.
See also Figure S6.interactwith a specific aspect of aneuploidy.Weobserve a corre-
lation between the degree of sensitivity to these compounds and
chromosome size, which is also seen with other traits shared by
trisomic MEFs (Williams et al., 2008). This correlation suggests
that the compounds synergize with the more general effects of
aneuploidy, rather than with the effects of gene copy number
imbalances of individual genes.
The effects of AICAR on trisomic MEFs were especially signif-
icant. The observation that knockdown of AMPK or treatment of
cells with the AMPK antagonist compound C suppressed the
antiproliferative effects of AICAR indicates that AICAR exerts
its function on trisomic MEFs, at least in part, through activating
AMPK. Other compounds that activate AMPK did not, however
show the same degree of efficacy as AICAR. The effects of
metformin on trisomic MEFs were subtle, and 2-deoxyglucose,
although causing AMPK activation, did not show selectivity for
trisomic cells. The differential effects of the different AMPK-
activating compounds may be explained by the finding that
AICAR, metformin, and 2-deoxyglucose activate AMPK via
different mechanisms. 2-deoxyglucose stimulates AMPK
through its inhibitory effects on glycolysis. Metformin is thought
to activate AMPK by inhibiting oxidative phosphorylation (Haw-
ley et al., 2010). In contrast to these indirect ways of activating
AMPK, AICAR is metabolized into ZMP in cells, which then binds
AMPK (Hawley et al., 2010). This direct interaction with AMPK
may have more dramatic effects in trisomic than euploid MEFs.
Mechanisms of Proliferation Inhibition
Our results indicate that AICAR, 17-AAG, and chloroquine
induce apoptosis in trisomic MEFs. The AICAR-induced
apoptosis is mediated by p53. Apoptosis caused by 17-AAG
and chloroquine also depends on p53, at least in trisomy 13 cells.
Simply activating p53 is, however, not sufficient to cause this
aneuploidy-specific apoptosis because DNA-damaging agents
(e.g., doxorubicin), which also activate p53 (Tomasini et al.,
2008), do not show selectivity. What then are the origins of the
aneuploidy selectivity of the three compounds? Our data provide
some insights into the synergism between aneuploidy and
AICAR. AICAR induces energy stress. This exaggerates the
already stressed state of aneuploid cells, as judged by higher
levels of autophagy and active Hsp72. We propose that this
increases the cell’s susceptibility to apoptosis. As AICAR also
activates p53 through AMPK, the combination of these events
induces apoptosis. The mechanisms whereby AICAR induces
autophagy are well established (Buzzai et al., 2007), but how it
increases the levels of the stress-induced chaperone Hsp72 is
not clear. In budding yeast, the heat shock response transcrip-
tion factor Hsf1, which induces the production of many chaper-
ones, is activated by the AMPK homolog Snf1 under glucose
starvation conditions (Tamai et al., 1994). A similar response of
the protein-folding pathways to AMPK activation could also exist
in mammalian cells.
How aneuploidy-induced stresses sensitize trisomic cells to
AICAR-induced apoptosis is not known. We did not detect
elevated levels of p53 in untreated trisomic MEFs nor hyperacti-
vation of p53 by AICAR. We did find that p53 is more readily acti-
vated by AICAR treatment in aneuploid cells. This could explain
the compound’s differential effects on aneuploid and euploidCell 144, 499–512, February 18, 2011 ª2011 Elsevier Inc. 509
cells. Alternatively, the increased susceptibility of trisomic MEFs
to apoptosis could be brought about by p53-independent mech-
anisms. Such independent mechanisms must, however, also
result in increased levels of Bax insertion into mitochondrial
membranes.We speculate that Bnip3 could be such an indepen-
dent mechanism. Bnip3, which is induced by a variety of
stresses in a p53-dependent and -independent manner and is
present at high levels in trisomic MEFs (Figure 5B), has been
shown to induce apoptosis in a variety of cell types, including
murine fibroblasts (Burton and Gibson, 2009).
A synergism analogous to that proposed for aneuploidy and
AICAR can be envisioned to exist between the aneuploid state
and the proteotoxic stress-inducing compounds 17-AAG and
chloroquine. The compounds could further exaggerate the pro-
teotoxic stress of aneuploid cells, predisposing them to p53-
mediated apoptosis.
Effects of AICAR and 17-AAG on Aneuploid Cancer Cells
The proliferation inhibitory effects of AICAR and 17-AAG in colon
cancer cell lines with multiple chromosomal abnormalities were
more pronounced than in cancer cells with only few numeric
karyotypic abnormalities. Their combined use especially had
significant effects on CIN cancer cell lines compared to euploid
control lines and MIN cancer cell lines, both in cell culture and
xenograft models. AICAR and 17-AAG most likely inhibit tumor
cell growth in multiple ways, but two observations argue that
different degrees of aneuploidy contribute to the differential
effects of the two compounds on MIN and CIN cell lines. First,
a synergism between AICAR and 17-AAG and the aneuploid
state is also seen in two types of primary aneuploid cells, trisomic
MEFs and MEFs with decreased chromosome segregation
fidelity. Second, the response to AICAR and 17-AAG treatment
is similar in CIN cells and trisomic MEFs. AICAR treatment
induces autophagy in both cell types. Hsp72 is induced in
MEFs and already elevated in the CIN cell lines even in the
absence of AICAR treatment.
In contrast to trisomic MEFs, inactivation of p53 does not
protect aneuploid CIN colon cancer and lung cancer cell lines
from death by AICAR and/or 17-AAG. We have not yet identified
themechanisms underlying this p53-independent sensitivity, but
the two compounds do appear to induce apoptosis in at least
two CIN cancer cell lines. We speculate that the aneuploidy-
associated stresses are high in cells with high-grade aneuploidy,
making conditions that further enhance these stresses a lethal
event. In trisomic MEFs, AICAR and/or 17-AAG also exaggerate
the adverse effects of aneuploidy, but in cell lines with low-grade
aneuploidies, such as the trisomic MEFs, this only sensitizes
cells to p53-mediated apoptosis.
Why the four aneuploid cell lines in which p53 is wild-type
(Caco2, A549, NCI-H1563, and NCI-H2347) were not more
sensitive to AICAR and/or 17-AAG than cell lines in which p53
is mutated is not yet clear either. It is possible that other compo-
nents of the p53 pathway are defective in these cell lines. Alter-
natively, the p53 wild-type cancer cell lines may have evolved
other mechanisms that help them cope with the adverse effects
of aneuploidy. Clearly, it will be important to determine how
AICAR and 17-AAG inhibit tumor cell proliferation and whether
the selectivity for high-grade aneuploidy holds true in other510 Cell 144, 499–512, February 18, 2011 ª2011 Elsevier Inc.tumor types. Similarly, understanding why AICAR is more effec-
tive in colon cancer cell lines than in lung cancer cell lines could
shed light on how different cancer types develop mechanisms
that allow them to tolerate proteotoxic and energy stress.
The observation that cancer cells lacking p53 are also sensi-
tive to 17-AAG and/or AICAR has important implications for
the potential use of the two compounds as cancer therapeutics.
17-AAG has been shown to exhibit antitumor activity in multiple
myeloma and anaplastic large cell lymphoma in clinical trials
(Georgakis et al., 2006; Taldone et al., 2008). AICAR is currently
not approved for use in humans. Our studies predict that the
combined use of AICAR and 17-AAG may be effective against
a broad spectrum of human tumors. Most cancers not only
lack p53, but are also highly aneuploid and thus likely to experi-
ence proteotoxic and energy stress. Our data raise the inter-
esting possibility that compounds that exaggerate these
stresses exhibit efficacy against many or perhaps all aneuploid
tumors.
EXPERIMENTAL PROCEDURES
All Experimental Procedures are described in detail in the Supplemental
Information.
Mouse Strains and Cell Lines
Mouse strains were obtained from the Jackson Laboratory and are described
in the Extended Experimental Procedures. Human cell lines were obtained
from ATCC. Littermate-derived euploid and trisomic primary MEFs were
described previously (Williams et al., 2008). All experiments were performed
in at least three independent trisomic cell lines and analyzed together with
euploid littermates that carried a single Robertsonian translocation. We used
MEFs at early passages (%p5) to ensure that karyotypic changes had not
yet occurred. Two independent Cdc20AAA MEFs were kindly provided by Dr.
P. Zhang; Bub1bH/H mice by Dr. J.M. van Deursen.
Mice Xenografts
Two MIN (HCT15 and LoVo) and two CIN (HT29 and SW620) cells were
inoculated s.c. into flanks of 6-week-old female nude mice. Seven days after
injection, animals were treated with daily i.p. injection of AICAR (500 mg/kg
body weight), 17-AAG (80 mg/kg body weight), or an equal volume of vehicle.
Number of animals analyzed: vehicle control: n = 4; AICAR: n = 3; 17-AAG
n = 3; AICAR+17-AAG: n = 5. Mice had to be sacrificed at day 25 due to tumor
size in the vehicle control group.
Statistics
All data are shown as the mean ± standard deviation. Means were compared
using the two-tailed Student’s t test. p < 0.05 was considered statistically
significant in all calculations. All data analyses were performed using the Prism
software package, version 4.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
seven figures, and three tables and can be found with this article online at
doi:10.1016/j.cell.2011.01.017.
ACKNOWLEDGMENTS
We thank H.-C. Chang and M. vander Heiden for discussions; M. Hemann for
the LMS vectors and shp53.1224; D. Sabatini for torin1; J.M. van Deursen for
Bub1bH/H mice; P. Zhang for Cdc20AAA MEF cells; and E. Vazile in the Koch
Institute Microscopy facility for assistance. We are grateful to M. Dunham,
M. Hemann, J. Lees, D. Sabatini, F. Solomon, and members of the Amon lab
for their critical reading of the manuscript. This work was supported by grants
from the Howard Hughes Medical Institute and the Curt W. and Kathy Marble
Cancer Research Fund. Y.-C.T. is supported by the Human Frontier Science
Program Fellowship.
Received: August 4, 2010
Revised: November 22, 2010
Accepted: January 17, 2011
Published online: February 10, 2011
REFERENCES
Albertson, D.G., Collins, C., McCormick, F., and Gray, J.W. (2003).
Chromosome aberrations in solid tumors. Nat. Genet. 34, 369–376.
Antonarakis, S.E., Lyle, R., Dermitzakis, E.T., Reymond, A., and Deutsch, S.
(2004). Chromosome 21 and down syndrome: from genomics to pathophysi-
ology. Nat. Rev. Genet. 5, 725–738.
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C.J., McLauchlan, H.,
Klevernic, I., Arthur, J.S., Alessi, D.R., and Cohen, P. (2007). The selectivity
of protein kinase inhibitors: a further update. Biochem. J. 408, 297–315.
Baker, D.J., Jeganathan, K.B., Cameron, J.D., Thompson, M., Juneja, S.,
Kopecka, A., Kumar, R., Jenkins, R.B., de Groen, P.C., Roche, P., and van
Deursen, J.M. (2004). BubR1 insufficiency causes early onset of aging-associ-
ated phenotypes and infertility in mice. Nat. Genet. 36, 744–749.
Bhattacharyya, N.P., Skandalis, A., Ganesh, A., Groden, J., and Meuth, M.
(1994). Mutator phenotypes in human colorectal carcinoma cell lines. Proc.
Natl. Acad. Sci. USA 91, 6319–6323.
Burton, T.R., and Gibson, S.B. (2009). The role of Bcl-2 family member BNIP3
in cell death and disease: NIPping at the heels of cell death. Cell Death Differ.
16, 515–523.
Buzzai, M., Jones, R.G., Amaravadi, R.K., Lum, J.J., DeBerardinis, R.J., Zhao,
F., Viollet, B., and Thompson, C.B. (2007). Systemic treatment with the antidi-
abetic drug metformin selectively impairs p53-deficient tumor cell growth.
Cancer Res. 67, 6745–6752.
Canto´, C., Gerhart-Hines, Z., Feige, J.N., Lagouge, M., Noriega, L., Milne, J.C.,
Elliott, P.J., Puigserver, P., and Auwerx, J. (2009). AMPK regulates energy
expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature
458, 1056–1060.
Corton, J.M., Gillespie, J.G., Hawley, S.A., and Hardie, D.G. (1995). 5-amino-
imidazole-4-carboxamide ribonucleoside. A specific method for activating
AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558–565.
Cunningham, D., Atkin, W., Lenz, H.J., Lynch, H.T., Minsky, B., Nordlinger, B.,
and Starling, N. (2010). Colorectal cancer. Lancet 375, 1030–1047.
DeBerardinis, R.J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S.,
and Thompson, C.B. (2007). Beyond aerobic glycolysis: transformed cells can
engage in glutamine metabolism that exceeds the requirement for protein and
nucleotide synthesis. Proc. Natl. Acad. Sci. USA 104, 19345–19350.
Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny,
G.D., Mitchison, T.J., Moskowitz, M.A., and Yuan, J. (2005). Chemical inhibitor
of nonapoptotic cell death with therapeutic potential for ischemic brain injury.
Nat. Chem. Biol. 1, 112–119.
Georgakis, G.V., Li, Y., Rassidakis, G.Z., Medeiros, L.J., and Younes, A.
(2006). The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126
in anaplastic large cell lymphoma irrespective of ALK expression. Exp.
Hematol. 34, 1670–1679.
Hardie, D.G. (2007). AMP-activated/SNF1 protein kinases: conserved guard-
ians of cellular energy. Nat. Rev. Mol. Cell Biol. 8, 774–785.
Hawley, S.A., Ross, F.A., Chevtzoff, C., Green, K.A., Evans, A., Fogarty, S.,
Towler, M.C., Brown, L.J., Ogunbayo, O.A., Evans, A.M., and Hardie, D.G.
(2010). Use of cells expressing gamma subunit variants to identify diverse
mechanisms of AMPK activation. Cell Metab. 11, 554–565.
Hodgkin, J. (2005). Karyotype, ploidy, and gene dosage. In WormBook, The
C. elegans Research Community, ed. 10.1895/wormbook.1.3.1, http://www.
wormbook.org.Jones, R.G., Plas, D.R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M.J.,
and Thompson, C.B. (2005). AMP-activated protein kinase induces a p53-
dependent metabolic checkpoint. Mol. Cell 18, 283–293.
Lamia, K.A., Sachdeva, U.M., DiTacchio, L., Williams, E.C., Alvarez, J.G.,
Egan, D.F., Vasquez, D.S., Juguilon, H., Panda, S., Shaw, R.J., et al. (2009).
AMPK regulates the circadian clock by cryptochrome phosphorylation and
degradation. Science 326, 437–440.
Larson, P.S., de las Morenas, A., Cerda, S.R., Bennett, S.R., Cupples, L.A.,
and Rosenberg, C.L. (2006). Quantitative analysis of allele imbalance supports
atypical ductal hyperplasia lesions as direct breast cancer precursors. J.
Pathol. 209, 307–316.
Levine, B., and Kroemer, G. (2008). Autophagy in the pathogenesis of disease.
Cell 132, 27–42.
Li, M., Fang, X., Wei, Z., York, J.P., and Zhang, P. (2009). Loss of spindle
assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis
in mice. J. Cell Biol. 185, 983–994.
Li, M., Fang, X., Baker, D.J., Guo, L., Gao, X., Wei, Z., Han, S., van Deursen,
J.M., and Zhang, P. (2010). The ATM-p53 pathway suppresses aneuploidy-
induced tumorigenesis. Proc. Natl. Acad. Sci. USA 107, 14188–14193.
Lin, H.Y., Lin, S.P., Chen, Y.J., Hung, H.Y., Kao, H.A., Hsu, C.H., Chen, M.R.,
Chang, J.H., Ho, C.S., Huang, F.Y., et al. (2006). Clinical characteristics and
survival of trisomy 18 in a medical center in Taipei, 1988-2004. Am. J. Med.
Genet. A. 140, 945–951.
Lindsley, D.L., Sandler, L., Baker, B.S., Carpenter, A.T., Denell, R.E., Hall, J.C.,
Jacobs, P.A., Miklos, G.L., Davis, B.K., Gethmann, R.C., et al. (1972).
Segmental aneuploidy and the genetic gross structure of the Drosophila
genome. Genetics 71, 157–184.
Luo, J., Solimini, N.L., and Elledge, S.J. (2009). Principles of cancer therapy:
oncogene and non-oncogene addiction. Cell 136, 823–837.
Mizushima, N., and Klionsky, D.J. (2007). Protein turnover via autophagy:
implications for metabolism. Annu. Rev. Nutr. 27, 19–40.
Mizushima, N., Levine, B., Cuervo, A.M., and Klionsky, D.J. (2008). Autophagy
fights disease through cellular self-digestion. Nature 451, 1069–1075.
Moerman, P., Fryns, J.P., van der Steen, K., Kleczkowska, A., and Lauweryns,
J. (1988). The pathology of trisomy 13 syndrome. A study of 12 cases. Hum.
Genet. 80, 349–356.
Niwa, O., Tange, Y., and Kurabayashi, A. (2006). Growth arrest and chromo-
some instability in aneuploid yeast. Yeast 23, 937–950.
Pavelka, N., Rancati, G., Zhu, J., Bradford, W.D., Saraf, A., Florens, L.,
Sanderson, B.W., Hattem, G.L., and Li, R. (2010). Aneuploidy confers quanti-
tative proteome changes and phenotypic variation in budding yeast. Nature
468, 321–325.
Rajagopalan, H., Nowak, M.A., Vogelstein, B., and Lengauer, C. (2003). The
significance of unstable chromosomes in colorectal cancer. Nat. Rev.
Cancer 3, 695–701.
Sarbassov, D.D., Ali, S.M., and Sabatini, D.M. (2005). Growing roles for the
mTOR pathway. Curr. Opin. Cell Biol. 17, 596–603.
Segal, D.J., and McCoy, E.E. (1974). Studies on Down’s syndrome in tissue
culture. I. Growth rates and protein contents of fibroblast cultures. J. Cell.
Physiol. 83, 85–90.
Shih, I.M., Zhou, W., Goodman, S.N., Lengauer, C., Kinzler, K.W., and
Vogelstein, B. (2001). Evidence that genetic instability occurs at an early stage
of colorectal tumorigenesis. Cancer Res. 61, 818–822.
Sotillo, R., Hernando, E., Dı´az-Rodrı´guez, E., Teruya-Feldstein, J., Cordo´n-
Cardo, C., Lowe, S.W., and Benezra, R. (2007). Mad2 overexpression
promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11, 9–23.
Taldone, T., Gozman, A., Maharaj, R., and Chiosis, G. (2008). Targeting Hsp90:
small-molecule inhibitors and their clinical development. Curr. Opin.
Pharmacol. 8, 370–374.
Tamai, K.T., Liu, X., Silar, P., Sosinowski, T., and Thiele, D.J. (1994). Heat
shock transcription factor activates yeast metallothionein gene expression inCell 144, 499–512, February 18, 2011 ª2011 Elsevier Inc. 511
response to heat and glucose starvation via distinct signalling pathways. Mol.
Cell. Biol. 14, 8155–8165.
Thompson, S.L., and Compton, D.A. (2008). Examining the link between chro-
mosomal instability and aneuploidy in human cells. J. Cell Biol. 180, 665–672.
Thompson, S.L., and Compton, D.A. (2010). Proliferation of aneuploid human
cells is limited by a p53-dependent mechanism. J. Cell Biol. 188, 369–381.
Tomasini, R., Mak, T.W., and Melino, G. (2008). The impact of p53 and p73 on
aneuploidy and cancer. Trends Cell Biol. 18, 244–252.
Torres, E.M., Dephoure, N., Panneerselvam, A., Tucker, C.M., Whittaker, C.A.,
Gygi, S.P., Dunham, M.J., and Amon, A. (2010). Identification of aneuploidy-
tolerating mutations. Cell 143, 71–83.512 Cell 144, 499–512, February 18, 2011 ª2011 Elsevier Inc.Torres, E.M., Sokolsky, T., Tucker, C.M., Chan, L.Y., Boselli, M., Dunham,
M.J., and Amon, A. (2007). Effects of aneuploidy on cellular physiology and
cell division in haploid yeast. Science 317, 916–924.
Vander Heiden, M.G., and Thompson, C.B. (1999). Bcl-2 proteins: regulators
of apoptosis or of mitochondrial homeostasis? Nat. Cell Biol. 1, E209–E216.
Weaver, B.A., Silk, A.D., Montagna, C., Verdier-Pinard, P., and Cleveland,
D.W. (2007). Aneuploidy acts both oncogenically and as a tumor suppressor.
Cancer Cell 11, 25–36.
Williams, B.R., Prabhu, V.R., Hunter, K.E., Glazier, C.M., Whittaker, C.A.,
Housman, D.E., and Amon, A. (2008). Aneuploidy affects proliferation and
spontaneous immortalization in mammalian cells. Science 322, 703–709.
Young, J.C., Moarefi, I., and Hartl, F.U. (2001). Hsp90: a specialized but
essential protein-folding tool. J. Cell Biol. 154, 267–273.
